Inmune Bio, Inc. — Director's Dealing 2021

Jun 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2021-06-22

Reporting Person: Ganjei James Kelly (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-22	Option (right to buy)	$17.49	A	19025	Acquired	2031-06-21	Common Stock (19025)	Direct

Footnotes

F1: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.